OCS Oculis Holding AG

NASDAQ
$7.39

Oculis Holding AG (OCS) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on November 3, 2026.

Oculis Holding AG Beat Consensus Estimates
Tuesday, November 3, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.54)
Rev est $320K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Oculis Holding AG

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.